journal article·2019-12-04Open access

Pretreatment of ghrelin protects H9c2 cells against hypoxia/reoxygenation-induced cell death via PI3K/AKT and AMPK pathways

Yanbo Chen, Honggang Wang, Yong Zhang, Zhengping Wang, Shanshan Liu, Lianqun Cui

Abstract

Ghrelin has been widely recognized as a key peptide in the cardiovascular system. This study detected the potential of ghrelin in MI management and tried to decode one of the possible underlying mechanisms. H9c2 cells were pretreated with ghrelin and were subjected to hypoxia/reoxygenation (H/R). CCK-8, flow cytometry, Western blot and LDH analysis were conducted to assess the changes in cell survival. LY294002 and Compound C were used to treat H9c2 cells for blocking PI3K/AKT and AMPK pathways, respectively. Ghrelin expression in H9c2 cells was suppressed by siRNA-mediated silencing to see the effects of endogenous ghrelin. We found that, following H/R, H9c2 cells viability was decreased, CyclinD1 and CDK4 were down-regulated, apoptosis was induced, the release of LDH was enhanced, and the expression levels of Cox-2 and iNOS were up-regulated. Ghrelin protected H9c2 cells against H/R induced these alterations. Besides, ghrelin activated PI3K/AKT and AMPK pathways even in H/R-stimulated cells. The protective effects of ghrelin against H/R-induced cell damage were all attenuated by the addition of LY294002 or Compound C. Moreover, endogenous inhibition of ghrelin significantly induced cell death of H9c2 cells. In conclusion, this study demonstrated that ghrelin pretreatment protected H9c2 cells against H/R-induced cell damage, possibly via PI3K/AKT and AMPK pathways.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Regulation of Appetite and Obesity · Adipose Tissue and Metabolism · Biochemical Analysis and Sensing Techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong University

Department of Cardiology, Weifang People’s Hospital

Department of Clinical Laboratory, Weifang People’s Hospital

Department of Ultrasonography, Weifang People’s Hospital

References (41)

Show source-provided references
1. 10.1038/4523010.1038/45230 ↗
2. 10.1097/CRD.000000000000011310.1097/CRD.0000000000000113 ↗
3. 10.5603/FHC.a2015.000410.5603/FHC.a2015.0004 ↗
4. 10.1016/j.lfs.2017.07.02310.1016/j.lfs.2017.07.023 ↗
5. 10.1016/j.peptides.2010.08.01910.1016/j.peptides.2010.08.019 ↗
6. 10.1007/s40519-018-0599-610.1007/s40519-018-0599-6 ↗
7. 10.1016/j.molmet.2012.08.00310.1016/j.molmet.2012.08.003 ↗
8. 10.1016/j.jjcc.2011.11.00210.1016/j.jjcc.2011.11.002 ↗
9. 10.1016/j.bbrc.2018.03.03110.1016/j.bbrc.2018.03.031 ↗
10. 10.1136/gutjnl-2016-31315710.1136/gutjnl-2016-313157 ↗
11. 10.3748/wjg.v23.i10.175810.3748/wjg.v23.i10.1758 ↗
12. 10.1016/j.lfs.2017.08.00410.1016/j.lfs.2017.08.004 ↗
13. 10.1210/jcem.86.12.811510.1210/jcem.86.12.8115 ↗
14. Zabarovskaja S, Freda P, Williams JJ, et al. Acylation of ghrelin is increased in heart failure and decreases post heart transplantation. SCJ. 2014;48:343–348.
15. 10.1161/01.CIR.0000149746.62908.BB10.1161/01.CIR.0000149746.62908.BB ↗
16. 10.1159/00048582010.1159/000485820 ↗
17. 10.1016/j.peptides.2012.06.02010.1016/j.peptides.2012.06.020 ↗
18. 10.12659/MSM.90809610.12659/MSM.908096 ↗
19. 10.1002/j.2040-4603.2015.tb00664.x10.1002/j.2040-4603.2015.tb00664.x ↗
20. Shen H, Yao Z, Zhao W, et al. miR-21 enhances the protective effect of loperamide on rat cardiomyocytes against hypoxia/reoxygenation, reactive oxygen species production and apoptosis via regulating Akap8 and Bard1 expression. Exp Ther Med. 2019;17:1312–1320.
21. 10.1002/cre2.13510.1002/cre2.135 ↗
22. 10.1016/j.bbrc.2015.04.02010.1016/j.bbrc.2015.04.020 ↗
23. 10.1590/S1807-5932200900030001610.1590/S1807-59322009000300016 ↗
24. 10.1080/13813455.2018.143775110.1080/13813455.2018.1437751 ↗
25. 10.1016/j.biopha.2018.03.01010.1016/j.biopha.2018.03.010 ↗
26. 10.1007/s00395-018-0671-410.1007/s00395-018-0671-4 ↗
27. 10.1620/tjem.231.23510.1620/tjem.231.235 ↗
28. 10.3892/mmr.2016.553510.3892/mmr.2016.5535 ↗
29. 10.1007/s11033-017-4098-z10.1007/s11033-017-4098-z ↗
30. 10.1016/j.peptides.2013.01.01210.1016/j.peptides.2013.01.012 ↗
31. 10.2174/15734031079023166210.2174/157340310790231662 ↗
32. 10.1007/s10616-017-0156-610.1007/s10616-017-0156-6 ↗
33. 10.1007/s11010-017-3094-x10.1007/s11010-017-3094-x ↗
34. 10.1016/j.bcp.2014.01.04010.1016/j.bcp.2014.01.040 ↗
35. 10.1016/j.bbrc.2017.03.11910.1016/j.bbrc.2017.03.119 ↗
36. 10.1016/j.yjmcc.2019.02.00810.1016/j.yjmcc.2019.02.008 ↗
37. 10.1016/j.tem.2015.05.01010.1016/j.tem.2015.05.010 ↗
38. 10.4103/0253-7613.17454510.4103/0253-7613.174545 ↗
39. 10.1021/acs.molpharmaceut.9b0015010.1021/acs.molpharmaceut.9b00150 ↗
40. 10.1016/j.jnutbio.2016.12.01710.1016/j.jnutbio.2016.12.017 ↗
41. 10.3892/etm.2016.340010.3892/etm.2016.3400 ↗